Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230178 · ClinicalTrials.gov registry record · Phase 3
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT00230178 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 280 participants.
The verdict
NCT00230178, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, open-label, parallel group study with three arms: * Rasburicase alone * Rasburicase followed by Allopurinol * Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three arms.
Interventions
- DRUG Allopurinol
- DRUG Rasburicase (SR29142)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230178
The ClinicalTrials.gov registry entry for NCT00230178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT00230178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230178 about?
NCT00230178 is a clinical study titled "Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome". This is a randomized, multi-center, open-label, parallel group study with three arms: * Rasburicase alone * Rasburicase followed by Allopurinol * Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three a...
What is the current status of trial NCT00230178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2004-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00230178?
The interventions under investigation include: Allopurinol (DRUG), Rasburicase (SR29142) (DRUG).
Who is sponsoring clinical trial NCT00230178?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.